To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of Odevixibat for treating processive familial intrahepatic cholestasis.
Answered on
2 December 2021
The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based recommendations for the National Health Service on whether licenced medicines represent a clinically and cost-effective use of resources.
NICE is currently appraising odevixibat for the treatment of progressive familial intrahepatic cholestasis through its highly specialised technologies programme and expects to publish final guidance in January 2022.
Answered by
Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.